...
首页> 外文期刊>Oncogenesis. >Nuclear FOXP3 inhibits tumor growth and induced apoptosis in hepatocellular carcinoma by targeting c-Myc
【24h】

Nuclear FOXP3 inhibits tumor growth and induced apoptosis in hepatocellular carcinoma by targeting c-Myc

机译:核狐p3通过靶向c-myc抑制肿瘤生长和诱导肝细胞癌的细胞凋亡

获取原文
           

摘要

The status of FOXP3 and its isoforms in hepatocellular carcinoma (HCC) is unclear. We aimed to investigate the expression and function of FOXP3 and its isoforms in HCC. The study was performed on 84 HCC patients, HCC cell lines and a mouse tumor model. The levels of FOXP3 and its isoforms were determined by nested PCR, quantitative real-time PCR and immunohistochemistry (IHC) staining. The correlation between their levels and clinicopathologic characteristics was analyzed. The full length of FOXP3 (FOXP3) and exon 3-deleted FOXP3 (FOXP3Δ3) were found to be the major isoforms in HCC. The levels of FOXP3Δ3 mRNA and protein in HCC tumor samples were not significantly different from their adjacent normal tissues. The high expression of FOXP3 protein in HCC patients showed a good overall survival. The overexpression of FOXP3 significantly reduced tumor cell proliferation, migration and invasion. The immunofluorescence result indicated that FOXP3 needed to be translocated into the nucleus to exert its inhibitory function. The luciferase assay demonstrated that FOXP3 could be synergistic with Smad2/3/4 to inhibit the oncogene c-Myc. The co-immunoprecipitation results further revealed that FOXP3 could interact with Smad2/3/4. The chromatin immunoprecipitation (ChIP) assay showed that both FOXP3 and Smad2/3/4 bound the promoter of the c-Myc to inhibit it. The in vivo mouse tumor model study confirmed the inhibitory effect of FOXP3. Collectively, the expression of tumor FOXP3 can inhibit the growth of HCC via suppressing c-Myc directly or indirectly via interacting with Smad2/3/4. Therefore, FOXP3 is a tumor suppressor in HCC.
机译:Foxp3及其在肝细胞癌(HCC)中的同种型的状态尚不清楚。我们的旨在探讨富申3的表达和功能及其在HCC中的同种型。该研究进行了84例HCC患者,HCC细胞系和小鼠肿瘤模型进行。通过巢式PCR,定量实时PCR和免疫组织化学(IHC)染色来确定FoxP3及其同种型的水平。分析了它们的水平与临床病理学特征之间的相关性。发现Foxp3(Foxp3)和外显子3缺失的Foxp3(Foxp3Δ3)的全长是HCC中的主要同种型。 HCC肿瘤样品中FoxP3Δ3mRNA和蛋白质的水平与其相邻的正常组织没有显着差异。 HCC患者Foxp3蛋白的高表达表现出良好的整体存活。 Foxp3的过表达显着降低了肿瘤细胞增殖,迁移和侵袭。免疫荧光结果表明Foxp3需要易于膨胀到核中以发挥其抑制功能。荧光素酶测定证明Foxp3可以与Smad2 / 3/4进行协同,以抑制癌基因C-myc。共免疫沉淀结果进一步揭示了Foxp3可以与Smad2 / 3/4相互作用。染色质免疫沉淀(芯片)测定表明,Foxp3和Smad2 / 3/4都结合了C-myc的启动子以抑制它。体内小鼠肿瘤模型研究证实了Foxp3的抑制作用。总的来说,肿瘤FoxP3的表达可以通过与Smad2 / 3/4相互作用来抑制C-Myc的通过抑制C-Myc来抑制HCC的生长。因此,Foxp3是HCC中的肿瘤抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号